Neoleukin Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -8.88 | -100% |
| P/S |
|
0 | 33.77 | -100% |
|
|
| P/BV |
|
0.2535 | 4.83 | -94.75% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
0.0337 | -22.17 | -100.15% |
|
|
| Ev/S |
|
0 | 22.57 | -100% |
|
|
| Ev/FCF |
|
0.0407 | 68.76 | -99.94% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.97 | -100% | -340768.66 | -100% |
| ROE |
|
-47.23 | 9.61 | -591.42% |
|
|
| ROA |
|
-40.13 | 0.3443 | -11755.51% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-56.34 | 15.45 | -464.7% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.2142 | -3.68 | -94.17% | -0.214 | +0.0675% |
| Nеt Debt/Ebitda |
|
0.4566 | -3.44 | -113.29% |
|
|
| Debt/Ratio |
|
0.1044 | 0.1986 | -47.43% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
-0.2161 | 10.32 | -102.09% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.541 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9598 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.541 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-98.2 | -57.64 | 70.37% | ||
| Growth impulse Ebitda in 5 years |
|
78.75 | -90.94 | -186.6% | ||
| Growth impulse Net Income in 5 years |
|
83.66 | -97.8 | -185.54% | ||
| Growth impulse FCF in 5 years |
|
47.84 | -108.72 | -144% | ||
| Growth impulse EPS in 5 years |
|
-72.37 | -142.05 | -49.05% |
IP Score
3.92/10
